In this episode, Jean-Michel Molina, MD, PhD, and Joseph J. Eron, Jr., MD, discuss results from key clinical trials on HIV prevention and treatment as well as sexually transmitted infection (STI) prevention presented at IDWeek and Glasgow 2024, including:

• PURPOSE 1 and 2 comparing lenacapavir injection vs oral TDF/FTC
• TRIO Health Cohort and OPERA examining long-acting cabotegravir as PrEP
• DOLCE comparing DTG/3TC as first-line therapy in treatment-naive patients with HIV
• PRIDOX evaluating the use of DoxyPEP on STI incidence in men who have sex with men on PrEP

Presenters:

Jean-Michel Molina, MD, PhD
Professor of Infectious Diseases
University of Paris Cité
Head of the Department of Infectious Diseases
Hospital Saint-Louis and lariboisière
Paris, France

Joseph J. Eron, Jr., MD
Professor of Medicine, School of Medicine
Herman and Louise Smith Distinguished Professor
Chief, Division of Infectious Diseases
Director, Clinical Core, UNC Center for AIDS Research
Adjunct Professor of Epidemiology, Gillings School of Global Public Health
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Link to full program: 
https://bit.ly/3BBaZvJ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.